FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013814008> ?p ?o ?g. }

• W2013814008 endingPage "494" @default.
• W2013814008 startingPage "484" @default.
• W2013814008 abstract "BACKGROUNDFew studies have prospectively reported outcomes in patients with pulmonary arterial hypertension (PAH) treated with epoprostenol in the modern-day era of oral therapy and combination treatments. The Registry to Prospectively Describe Use of Epoprostenol for Injection (Veletri, prolonged room temperature stable-epoprostenol [RTS-Epo]) in Patients with Pulmonary Arterial Hypertension (PROSPECT) was established to prospectively describe the course of PAH in patients prescribed RTS-Epo.METHODSPROSPECT is a multicenter, US-based drug registry of primarily group 1 patients with PAH treated with RTS-Epo who were parenteral-naive or parenteral-transitioned at enrollment. Patients were followed until discontinuation of RTS-Epo, withdrawal, loss to follow-up, death, or end of study (maximum 1 year). One-year freedom from hospitalization (FH) and survival estimates were summarized by prostacyclin history (parenteral-naive or parenteral-transitioned), sex, and chronic renal insufficiency (CRI).RESULTSA total of 336 patients were included. The overall 1-year FH estimate was 51.0% ! 2.8% and was lower in parenteral-naive patients than parenteral-transitioned patients (42.8% ! 4.3% vs 57.1% ! 3.7%, respectively; P = .002). FH estimates were lower in male patients than female patients (38.3% ! 5.9% vs 54.6% ! 3.2%, respectively; P < .015) and in patients with CRI than patients without CRI (17.0% ! 8.4% vs 53.7% ! 2.9%, respectively; P < .001). The overall 1-year survival estimate was 84.0% ! 2.1%. Survival was poorer in parenteral-naive patients, male patients, and patients with CRI.CONCLUSIONSRisk of hospitalization and mortality remain high in patients with PAH. In particular, patients who are parenteral-naive at initiation of RTS-Epo therapy, male patients, and patients with CRI require close monitoring and aggressive clinical management. Few studies have prospectively reported outcomes in patients with pulmonary arterial hypertension (PAH) treated with epoprostenol in the modern-day era of oral therapy and combination treatments. The Registry to Prospectively Describe Use of Epoprostenol for Injection (Veletri, prolonged room temperature stable-epoprostenol [RTS-Epo]) in Patients with Pulmonary Arterial Hypertension (PROSPECT) was established to prospectively describe the course of PAH in patients prescribed RTS-Epo. PROSPECT is a multicenter, US-based drug registry of primarily group 1 patients with PAH treated with RTS-Epo who were parenteral-naive or parenteral-transitioned at enrollment. Patients were followed until discontinuation of RTS-Epo, withdrawal, loss to follow-up, death, or end of study (maximum 1 year). One-year freedom from hospitalization (FH) and survival estimates were summarized by prostacyclin history (parenteral-naive or parenteral-transitioned), sex, and chronic renal insufficiency (CRI). A total of 336 patients were included. The overall 1-year FH estimate was 51.0% ! 2.8% and was lower in parenteral-naive patients than parenteral-transitioned patients (42.8% ! 4.3% vs 57.1% ! 3.7%, respectively; P = .002). FH estimates were lower in male patients than female patients (38.3% ! 5.9% vs 54.6% ! 3.2%, respectively; P < .015) and in patients with CRI than patients without CRI (17.0% ! 8.4% vs 53.7% ! 2.9%, respectively; P < .001). The overall 1-year survival estimate was 84.0% ! 2.1%. Survival was poorer in parenteral-naive patients, male patients, and patients with CRI. Risk of hospitalization and mortality remain high in patients with PAH. In particular, patients who are parenteral-naive at initiation of RTS-Epo therapy, male patients, and patients with CRI require close monitoring and aggressive clinical management." @default.
• W2013814008 created "2016-06-24" @default.
• W2013814008 creator A5002770727 @default.
• W2013814008 creator A5010219489 @default.
• W2013814008 creator A5021047743 @default.
• W2013814008 creator A5025010514 @default.
• W2013814008 creator A5031249497 @default.
• W2013814008 creator A5032869220 @default.
• W2013814008 creator A5040793677 @default.
• W2013814008 creator A5052565303 @default.
• W2013814008 creator A5056518661 @default.
• W2013814008 creator A5056570032 @default.
• W2013814008 creator A5070323256 @default.
• W2013814008 creator A5078732560 @default.
• W2013814008 date "2015-02-01" @default.
• W2013814008 modified "2023-09-24" @default.
• W2013814008 title "Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study" @default.
• W2013814008 cites W1643375850 @default.
• W2013814008 cites W1988590913 @default.
• W2013814008 cites W1994219663 @default.
• W2013814008 cites W1995110919 @default.
• W2013814008 cites W1999594706 @default.
• W2013814008 cites W2017134753 @default.
• W2013814008 cites W2028590696 @default.
• W2013814008 cites W2034444514 @default.
• W2013814008 cites W2037502378 @default.
• W2013814008 cites W2071419761 @default.
• W2013814008 cites W2085328300 @default.
• W2013814008 cites W2087664540 @default.
• W2013814008 cites W2114374604 @default.
• W2013814008 cites W2114863766 @default.
• W2013814008 cites W2117339256 @default.
• W2013814008 cites W2131210896 @default.
• W2013814008 cites W2131897774 @default.
• W2013814008 cites W2134594367 @default.
• W2013814008 cites W2136203952 @default.
• W2013814008 cites W2140148084 @default.
• W2013814008 cites W2140319297 @default.
• W2013814008 cites W2150343952 @default.
• W2013814008 cites W2151863430 @default.
• W2013814008 cites W2166964193 @default.
• W2013814008 cites W2321522617 @default.
• W2013814008 doi "https://doi.org/10.1378/chest.14-1004" @default.
• W2013814008 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4314821" @default.
• W2013814008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25320967" @default.
• W2013814008 hasPublicationYear "2015" @default.
• W2013814008 type Work @default.
• W2013814008 sameAs 2013814008 @default.
• W2013814008 citedByCount "34" @default.
• W2013814008 countsByYear W20138140082016 @default.
• W2013814008 countsByYear W20138140082017 @default.
• W2013814008 countsByYear W20138140082018 @default.
• W2013814008 countsByYear W20138140082019 @default.
• W2013814008 countsByYear W20138140082020 @default.
• W2013814008 countsByYear W20138140082021 @default.
• W2013814008 countsByYear W20138140082022 @default.
• W2013814008 countsByYear W20138140082023 @default.
• W2013814008 crossrefType "journal-article" @default.
• W2013814008 hasAuthorship W2013814008A5002770727 @default.
• W2013814008 hasAuthorship W2013814008A5010219489 @default.
• W2013814008 hasAuthorship W2013814008A5021047743 @default.
• W2013814008 hasAuthorship W2013814008A5025010514 @default.
• W2013814008 hasAuthorship W2013814008A5031249497 @default.
• W2013814008 hasAuthorship W2013814008A5032869220 @default.
• W2013814008 hasAuthorship W2013814008A5040793677 @default.
• W2013814008 hasAuthorship W2013814008A5052565303 @default.
• W2013814008 hasAuthorship W2013814008A5056518661 @default.
• W2013814008 hasAuthorship W2013814008A5056570032 @default.
• W2013814008 hasAuthorship W2013814008A5070323256 @default.
• W2013814008 hasAuthorship W2013814008A5078732560 @default.
• W2013814008 hasBestOaLocation W20138140081 @default.
• W2013814008 hasConcept C126322002 @default.
• W2013814008 hasConcept C141071460 @default.
• W2013814008 hasConcept C188816634 @default.
• W2013814008 hasConcept C23131810 @default.
• W2013814008 hasConcept C2778715236 @default.
• W2013814008 hasConcept C71924100 @default.
• W2013814008 hasConcept C78722104 @default.
• W2013814008 hasConceptScore W2013814008C126322002 @default.
• W2013814008 hasConceptScore W2013814008C141071460 @default.
• W2013814008 hasConceptScore W2013814008C188816634 @default.
• W2013814008 hasConceptScore W2013814008C23131810 @default.
• W2013814008 hasConceptScore W2013814008C2778715236 @default.
• W2013814008 hasConceptScore W2013814008C71924100 @default.
• W2013814008 hasConceptScore W2013814008C78722104 @default.
• W2013814008 hasIssue "2" @default.
• W2013814008 hasLocation W20138140081 @default.
• W2013814008 hasLocation W20138140082 @default.
• W2013814008 hasLocation W20138140083 @default.
• W2013814008 hasLocation W20138140084 @default.
• W2013814008 hasOpenAccess W2013814008 @default.
• W2013814008 hasPrimaryLocation W20138140081 @default.
• W2013814008 hasRelatedWork W2003938723 @default.
• W2013814008 hasRelatedWork W2025680102 @default.
• W2013814008 hasRelatedWork W2047967234 @default.
• W2013814008 hasRelatedWork W2118496982 @default.
• W2013814008 hasRelatedWork W2157096003 @default.
• W2013814008 hasRelatedWork W2439875401 @default.

• next